中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

750 records (took 0.071 seconds)

    AQUEOUS ACYCLOVIR FORMULATION AND METHOD FOR STORING SAME
    292.
    发明申请
    AQUEOUS ACYCLOVIR FORMULATION AND METHOD FOR STORING SAME 审中-公开
    水性ACYCLOVIR配方及其储存方法

    公开(公告)号：WO1997017934A1

    公开(公告)日：1997-05-22

    申请号：PCT/US1996017615

    申请日：1996-11-04

    Applicant: ABBOTT LABORATORIES

    Inventor： ABBOTT LABORATORIES ,  RHODES, Lawrence, J. ,  KLANDRUD, Kathee, E.

    IPC: A61J01/00

    CPC classification number: A61J1/00

    Abstract: A method for storing a solution containing acyclovir and a pharmaceutical product containing an acyclovir solution. The method includes the steps of providing a predetermined volume of an acyclovir solution suitable for parenteral administration to a patient and providing a container constructed to contain the predetermined volume. The container is constructed from a material containing polymethylpentene and defines an opening. The acyclovir solution is placed into the container. The method further includes the step of providing a stopper configured to seal fluidly the opening defined by the container. The container is then sealed using the stopper. The pharmaceutical product includes an acyclovir solution contained by a container constructed from a material containing polymethylpentene. The container defines an opening therethrough. The product further includes a stopper coated with a fluorinated resin. The stopper fluidly seals the opening defined by the container.

    Abstract translation: 一种用于储存含有阿昔洛韦和含有阿昔洛韦溶液的药物的溶液的方法。 该方法包括以下步骤：提供适合于向患者肠胃外给药的预定体积的阿昔洛韦溶液，并提供构造成容纳预定体积的容器。 容器由含有聚甲基戊烯的材料构成并限定开口。 将阿昔洛韦溶液置于容器中。 该方法进一步包括提供一个止动器的步骤，该止动器构造成将流体密封由容器限定的开口。 然后使用塞子密封容器。 药物产品包括由含有聚甲基戊烯的材料构成的容器所含的阿昔洛韦溶液。 容器限定穿过其中的开口。 该产品还包括涂覆有氟化树脂的塞子。 止动器流体地密封由容器限定的开口。

    PROCESS FOR MAKING CRYSTALLINE IRON DEXTRAN
    294.
    发明申请
    PROCESS FOR MAKING CRYSTALLINE IRON DEXTRAN 审中-公开
    制造水晶铁矿石的工艺

    公开(公告)号：WO1997017377A1

    公开(公告)日：1997-05-15

    申请号：PCT/US1996018018

    申请日：1996-11-08

    Applicant: ABBOTT LABORATORIES

    Inventor： ABBOTT LABORATORIES ,  MONTE, William, T. ,  SCAGGS, Laurie

    IPC: C08B37/02

    CPC classification number: C08B37/0021

    Abstract: A process for the crystallization of an iron-dextran complex in readily-filterable form comprising adding slowly, with stirring, an acidified aqueous iron-dextran solution to a vessel containing a water miscible organic solvent such as methanol, as well as crystalline iron-dextran complexes so prepared.

    Abstract translation: 一种易于过滤形式的铁 - 葡聚糖络合物结晶的方法，包括在搅拌下将酸化的水性铁 - 葡聚糖溶液缓慢加入到含有水混溶性有机溶剂如甲醇的容器中，以及结晶铁 - 葡聚糖 复合体如此准备。

    3-DEOXY-3-DESCLADINOSE DERIVATIVES OF ERYTHROMYCINS A AND B
    295.
    发明申请
    3-DEOXY-3-DESCLADINOSE DERIVATIVES OF ERYTHROMYCINS A AND B 审中-公开
    3-甲氧基-3-脱氧霉素衍生物

    公开(公告)号：WO1997017357A1

    公开(公告)日：1997-05-15

    申请号：PCT/US1996017892

    申请日：1996-11-06

    Applicant: ABBOTT LABORATORIES

    Inventor： ABBOTT LABORATORIES ,  OR, Yat, Sun ,  CHU, Daniel, T. ,  ELLIOTT, Richard, L. ,  PIREH, Daisy

    IPC: C07H17/08

    CPC classification number: C07H17/08

    Abstract: A compound selected from groups (I), (II), and (III), wherein A, B, V, W, X and R are specifically defined; pharmaceutical compositions thereof; a method of treating or preventing bacterial infections by administering therapeutically effective pharmaceutical compositions thereof; and a process for the preparation thereof.

    Abstract translation: 选自基团（I），（II）和（III）的化合物，其中A，B，V，W，X和R 8是具体定义的; 其药物组合物; 通过施用其治疗有效的药物组合物来治疗或预防细菌感染的方法; 及其制备方法。

    BIS-HETEROARYLYLMETHOXYPHENYLKETONE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS
    298.
    发明申请
    BIS-HETEROARYLYLMETHOXYPHENYLKETONE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS 审中-公开
    作为紫苏酮生物合成酶抑制剂的双异氟醚甲基酮衍生物

    公开(公告)号：WO1997012866A1

    公开(公告)日：1997-04-10

    申请号：PCT/US1996015278

    申请日：1996-09-25

    Applicant: ABBOTT LABORATORIES

    Inventor： ABBOTT LABORATORIES ,  BROOKS, Clint, D., W. ,  BHATIA, Pramila ,  KOLASA, Theodozyj

    IPC: C07D215/14

    CPC classification number: C07D213/30 ,  C07D213/36 ,  C07D215/14 ,  C07D215/18 ,  C07D235/12 ,  C07D239/26 ,  C07D241/42 ,  C07D263/56 ,  C07D277/24 ,  C07D277/64 ,  C07D417/14

    Abstract: Compounds having formula (I) or a pharmaceutically acceptable salt thereof wherein W is selected from the group consisting of optionally substituted quinolyl, optionally substituted benzothiazolyl, optionally substituted benzoxazolyl, optionally substituted benzimidazolyl, optionally substituted quinoxalyl, optionally substituted pyridyl, optionally substituted pyrimidyl, and optionally substituted thiazolyl; R and R are one or more groups independently selected from hydrogen, alkyl, haloalkyl, alkoxy, and halogen; Z is selected from the group consisting of N-OH, N-O-A-COM, CH-COM, and CH-CH=N-O-A-COM wherein A is selected from the group consisting of alkylene, alkenylene, cycloalkylene, and optionally substituted alkylphenyl wherein the alkyl portion is of one to six carbon atoms, and M is selected from the group consisting of a pharmaceutically acceptable, metabolically cleavable group, -OR , and -NR R , inhibit leukotriene biosynthesis and are useful in the treatment of allergic and inflammatory disease states. Also disclosed are leukotriene biosynthesis inhibiting compositions and a method of inhibiting leukotriene biosynthesis.

    Abstract translation: 具有式（I）化合物或其药学上可接受的盐，其中W选自任选取代的喹啉基，任选取代的苯并噻唑基，任选取代的苯并恶唑基，任选取代的苯并咪唑基，任选取代的喹喔啉基，任选取代的吡啶基，任选取代的嘧啶基，和 任选取代的噻唑基; R 1和R 2是一个或多个独立地选自氢，烷基，卤代烷基，烷氧基和卤素的基团; Z选自N-OH，NOA-COM，CH-COM和CH-CH = NOA-COM，其中A选自亚烷基，亚烯基，亚环烷基和任选取代的烷基苯基，其中烷基 部分为1至6个碳原子，M选自药学上可接受的，代谢可裂解基团-OR 3和-NR 4 R 5，抑制白三烯生物合成，并且可用于 治疗过敏和炎症疾病状态。 还公开了白三烯生物合成抑制组合物和抑制白三烯生物合成的方法。

    SYMMETRICAL BISHETEROARYL-METHOXYPHENYL-IMINOXYALKYL-CARBOXYLATES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS
    299.
    发明申请
    SYMMETRICAL BISHETEROARYL-METHOXYPHENYL-IMINOXYALKYL-CARBOXYLATES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS 审中-公开
    对称双羟基 - 甲氧基苯基 - 甲氧基羰基羧酸酯，它们的制备及其作为紫苏酮生物合成的抑制剂

    公开(公告)号：WO1997012865A1

    公开(公告)日：1997-04-10

    申请号：PCT/US1996015241

    申请日：1996-09-24

    Applicant: ABBOTT LABORATORIES

    Inventor： ABBOTT LABORATORIES ,  BROOKS, Clint, D., W. ,  BHATIA, Pramila ,  KOLASA, Theodozyj

    IPC: C07D215/14

    CPC classification number: C07D213/30 ,  C07D215/14 ,  C07D215/18 ,  C07D235/12 ,  C07D239/26 ,  C07D241/42 ,  C07D263/56 ,  C07D277/24 ,  C07D277/64 ,  C07D417/14

    Abstract: Compounds having formula (I) or a pharmaceutically acceptable salt thereof wherein W and Y at each occurrence are the same and W is selected from the group consisting of optionally substituted quinolyl, optionally substituted benzothiazolyl, optionally substituted benzoxazolyl, optionally substituted benzimidazolyl, optionally substituted quinoxalyl, optionally substituted pyridyl, optionally substituted pyrimidyl, and optionally substituted thiazolyl; Y is selected from optionally substituted phenylene and optionally substituted (c) wherein the alkylene portion is of one to six carbon atoms; A is selected from alkylene, alkenylene, cycloalkylene, and optionally substituted (d) wherein the alkylene portion is of one to six carbon atoms: and M is selected from hydrogen, a pharmaceutically acceptable cation, a metabolically cleavable group, -OR , and -NR R , inhibit leukotriene biosynthesis and are useful in the treatment of allergic and inflammatory disease states. Also disclosed are leukotriene biosynthesis inhibiting compositions and a method of inhibiting leukotriene biosynthesis in a mammal.

    Abstract translation: 具有式（I）的化合物或其药学上可接受的盐，其中W和Y在每次出现时相同，W选自任选取代的喹啉基，任选取代的苯并噻唑基，任选取代的苯并恶唑基，任选取代的苯并咪唑基，任选取代的喹喔啉基 ，任选取代的吡啶基，任选取代的嘧啶基和任选取代的噻唑基; Y选自任选取代的亚苯基和任选取代的（c），其中亚烷基部分具有1至6个碳原子; A选自亚烷基，亚烯基，亚环烷基和任选取代的（d），其中亚烷基部分具有1-6个碳原子：M选自氢，可药用阳离子，代谢断裂基团-OR 3 和-NR 4 R 5抑制白三烯生物合成，并且可用于治疗过敏性和炎性疾病状态。 还公开了白三烯生物合成抑制组合物和抑制哺乳动物中白细胞三烯生物合成的方法。

Patent Agency Ranking